This syndrome comprises vitamin D deficiency, vascular calcification, abnormalities in bone turnover, altered metabolism of calcium and phosphate, and increased levels of fibroblast growth factor-23 (FGF-23) and parathyroid hormone (PTH), known as secondary hyperparathyroidism (SHPT). This evidence concerns the gene FGF23 and secondary hyperparathyroidism.